Investment
Trophos SA, of Marseille, France, a specialist in treatments for central nervous system diseases, has raised €8.5 million in a third financing round, enabling it to complete Phase II studies of TRO19622, for the treatment of neuropathic pain and motor neurone diseases, and to accelerate the development of TRO40303 to clinical proof-of-concept for ischemia-reperfusion injury.
The financing was led by new investor OTC Asset Management with CM-CIC Capital Privé. Current investors Society General Asset Management, Viveris Management, Turenne Capital Partners, Blue Medical and the Association Française contre les Myopathies (AFM) all followed on. Paul-Henry Schmelck, a partner at OTC Asset Management, joins the supervisory board of Trophos.
“The financial support Trophos has received from these new and existing investors reflects the excitement we all share as the company approaches a series of key clinical milestones,” said Antoine Béret, CEO of Trophos.
“We are also pleased that the AFM has reaffirmed its support for our spinal muscular atrophy (SMA) clinical programmed by taking part in this round.”
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
